Last reviewed · How we verify

NCT02378129

Evaluation of Dentin Hypersensitivity Using Glass Ionomer Cements

Completed Phase 2, PHASE3 Last updated 17 August 2020
What this trial tests

Phase 2, PHASE3 trial testing Resin-modified glass ionomer cement Clinpro XT in Dentin Hypersensitivity in 20 participants. Completed in 1 April 2015.

Timeline
2 April 2014
Primary endpoint
1 April 2015
1 April 2015

Quick facts

Lead sponsorFederal University of Pelotas
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment20
Start date2 April 2014
Primary completion1 April 2015
Estimated completion1 April 2015

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of Pelotas

Who can join

Adults 28 to 70, any sex, with Dentin Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this randomized, double-blind, split-mouth clinical trial is to evaluate and compare the desensitizing efficacies of the resin-modified glass ionomer cement ClinproTM XT (3M ESPE, Minnesota, USA) and the conventional glass ionomer cement Vidrion R (SS White, Gloucester, UK) at 2-year follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dentin Hypersensitivity

Currently open trials in the same condition.

Other Federal University of Pelotas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02378129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing